Bevacizumab-800cw (** Currently investigational - no approved brand names (Generic: bevacizumab-IRDye800CW) **)

Other Medications

1 Clinical Trials

Description

Bevacizumab-800cw is an investigational medication currently being studied for its potential to improve the detection of precancerous lesions in the gastrointestinal tract, including the colon. It is not a treatment for colorectal cancer itself, but rather a tool used during endoscopic procedures. This medication is a special version of bevacizumab, a drug already used to treat certain cancers, which has been linked to a fluorescent dye (IRDye800CW). This dye allows researchers to use special imaging techniques (like near-infrared fluorescence and immuno-OCT) to highlight areas where blood vessel growth factors (specifically VEGF-A) are highly active. High levels of these factors can indicate the presence of early, potentially cancerous changes. The goal is to help doctors see these subtle changes more clearly during colonoscopies or endoscopies, potentially leading to earlier detection and removal of polyps or precancerous lesions, which could reduce the risk of developing colorectal cancer. It is currently being evaluated in clinical trials for safety and feasibility.

Mechanism of Action

Bevacizumab is a monoclonal antibody that targets Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a protein that stimulates the growth of new blood vessels (angiogenesis). By binding to VEGF-A, bevacizumab prevents it from interacting with its receptors on the surface of endothelial cells (cells lining blood vessels). This inhibition reduces the formation of new blood vessels, which tumors need to grow and spread. In the context of bevacizumab-800cw, the bevacizumab antibody is attached to a fluorescent dye (IRDye800CW). This allows the targeted binding to VEGF-A in tissues to be visualized using fluorescence imaging techniques during endoscopic procedures. The fluorescence highlights areas with high VEGF-A activity, potentially indicating precancerous lesions.

Side Effects

Bevacizumab-800cw is an investigational agent used for diagnostic imaging Not treatment. Therefore Its side effect profile is primarily related to its use as a tracer during endoscopic procedures. The safety and feasibility of the imaging system using this tracer are being evaluated in clinical trials (NCT06008522). As it is linked to bevacizumab Potential side effects associated with bevacizumab itself (when used as a treatment) include hypertension Bleeding And thromboembolic events. However The specific side effects related to the diagnostic use of bevacizumab-800cw are still being evaluated in ongoing trials. The trial description focuses on safety and feasibility of the imaging system Suggesting potential risks related to the procedure or the tracer itself are under investigation.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06008522 Not Applicable
Unknown
Safety and Feasibility of Immuno-OCT

Quick Info

Brand Name** Currently investigational - no approved brand names (Generic: bevacizumab-IRDye800CW) **
CategoryOther Medications
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.